{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:01Z","timestamp":1791335641798,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtho.2024.01.016","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T02:07:22Z","timestamp":1712196442000},"page":"541-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma"],"prefix":"10.1016","volume":"19","author":[{"given":"Steven G.","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Meirson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1578-2637","authenticated-orcid":false,"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.01.016_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12890-021-01513-7","article-title":"Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma","volume":"21","author":"Gray","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jtho.2024.01.016_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1078-0432.CCR-21-1466","article-title":"FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.01.016_bib3","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2024.01.016_bib4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2023.1675","article-title":"The ethics of clinical research: managing persistent uncertainty","volume":"329","author":"London","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2024.01.016_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12967-022-03744-6","article-title":"Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology","volume":"20","author":"Meirson","year":"2022","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2024.01.016_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1490","article-title":"Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma","volume":"5","author":"Meirson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2024.01.016_bib7","first-page":"2531","article-title":"Immunotherapy vs. chemotherapy in subsequent treatment of malignant pleural mesothelioma: which is better?","volume":"12","author":"Guo","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtho.2024.01.016_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtho.2023.08.004","article-title":"Meta-analysis on the combination of chemotherapy with programmed death-ligand 1 and programmed cell death protein 1 blockade as first-line treatment for unresectable pleural mesothelioma","volume":"19","author":"Tagliamento","year":"2024","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib9","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2023.3295","article-title":"Nivolumab plus ipilimumab vs nivolumab alone in advanced cancers other than melanoma: a meta-analysis","volume":"9","author":"Serritella","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2024.01.016_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.semradonc.2023.06.007","article-title":"Challenges, complexities, and considerations in the design and interpretation of late-phase oncology trials","volume":"33","author":"Lin","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib13","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.01.016_bib14","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/j.jtho.2023.09.678","article-title":"P2.18-05 Impact of evolving treatment paradigms on survival outcomes in advanced pleural mesothelioma: a real-world analysis","volume":"18","author":"Wu","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib15","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/j.jtho.2023.09.677","article-title":"P2.18-04 real-world study on efficacy of first-line nivolumab\u00a0+ ipilimumab in unresectable malignant pleural mesothelioma (ImmunoMeso)","volume":"18","author":"Aguirre","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma \u2013 RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib17","article-title":"A\u00a0real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern","volume":"3","author":"Kerrigan","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2024.01.016_bib18","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib19","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib20","article-title":"JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma","volume":"9","author":"Miyamoto","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.01.016_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11096-023-01662-1","article-title":"Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma","volume":"46","author":"Lang","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jtho.2024.01.016_bib23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s40273-023-01305-3","article-title":"Cost effectiveness and budget impact of nivolumab plus ipilimumab versus platinum plus pemetrexed (with and without bevacizumab) in patients with unresectable malignant pleural mesothelioma in Switzerland","volume":"41","author":"Barbier","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jtho.2024.01.016_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13023-023-02925-w","article-title":"First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis","volume":"18","author":"Yang","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtho.2024.01.016_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221116604","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma","volume":"14","author":"Yang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtho.2024.01.016_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.947375","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma","volume":"10","author":"Ye","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.jtho.2024.01.016_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-073724","article-title":"Registry study of immune-related adverse events using electronic patient-reported outcome in patients with cancer receiving immune checkpoint inhibitors: protocol for a multicentre cohort study","volume":"13","author":"Hirata","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtho.2024.01.016_bib26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2023.06.011","article-title":"European epidemiology of pleural mesothelioma-real-life data from a joint analysis of the Mesoscape database of the European Thoracic Oncology platform and the European Society of Thoracic Surgery Mesothelioma database","volume":"18","author":"Opitz","year":"2023","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:44Z","timestamp":1761562364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1556086424000364"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.01.016","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}